In September 2003, three pharmaceutical companies, Cambridge Antibody Technology, Micromet AG and Enzon Pharmaceuticals, announced that they had signed a non-exclusive cross-license agreement. In the agreement, all three parties obtained substantial "freedom to operate" authorizing each other to use some of their respective patented technology. This enabled them to conduct research and develop a defined number of therapeutic and diagnostic antibody-based products.
展开▼
